nivolumab,ipilimumab
bms
['niche-2']
niche-2 included 107 patients pathological complete response 95%%
pathological response 67 %
61% w (mild) aes 100% r0 resections #esmo22 #immunotherapy 
Focused on #PrecisionOncology ?? & #PancreaticCancer ?? •@myesmo faculty •Rolling with @OncoAlert?? •????#MissionCancer Board •Views are my own•